Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
PharmaMar and Key Oncologics Have Signed an Exclusive Agreement to Commercialize Yondelis®
Details : PharmaMar will retain exclusive production rights for Yondelis®(trabectedin), which will be sold to Key Oncologics for its clinical and commercial use in South Africa, Namibia and Botswana.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 19, 2020
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?